- Home
- IMUX vs OFS Comparison
IMUX vs OFS Comparison
Compare IMUX & OFS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMUX
- OFS
- Stock Information
- Founded
- IMUX 2016
- OFS 2001
- Country
- IMUX United States
- OFS United States
- Employees
- IMUX N/A
- OFS N/A
- Industry
- IMUX Biotechnology: Pharmaceutical Preparations
- OFS Finance/Investors Services
- Sector
- IMUX Health Care
- OFS Finance
- Exchange
- IMUX Nasdaq
- OFS Nasdaq
- Market Cap
- IMUX 110.8M
- OFS 109.9M
- IPO Year
- IMUX N/A
- OFS 2012
- Fundamental
- Price
- IMUX $1.06
- OFS $8.02
- Analyst Decision
- IMUX Strong Buy
- OFS
- Analyst Count
- IMUX 5
- OFS 0
- Target Price
- IMUX $13.20
- OFS N/A
- AVG Volume (30 Days)
- IMUX 1.5M
- OFS 46.0K
- Earning Date
- IMUX 11-07-2024
- OFS 10-31-2024
- Dividend Yield
- IMUX N/A
- OFS 16.96%
- EPS Growth
- IMUX N/A
- OFS N/A
- EPS
- IMUX N/A
- OFS N/A
- Revenue
- IMUX N/A
- OFS $49,799,000.00
- Revenue This Year
- IMUX N/A
- OFS N/A
- Revenue Next Year
- IMUX N/A
- OFS N/A
- P/E Ratio
- IMUX N/A
- OFS N/A
- Revenue Growth
- IMUX N/A
- OFS N/A
- 52 Week Low
- IMUX $0.97
- OFS $7.75
- 52 Week High
- IMUX $2.11
- OFS $12.41
- Technical
- Relative Strength Index (RSI)
- IMUX 28.31
- OFS 43.72
- Support Level
- IMUX $1.15
- OFS $7.99
- Resistance Level
- IMUX $1.28
- OFS $8.09
- Average True Range (ATR)
- IMUX 0.08
- OFS 0.14
- MACD
- IMUX -0.01
- OFS 0.00
- Stochastic Oscillator
- IMUX 12.90
- OFS 42.00
About IMUX Immunic Inc.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.
About OFS OFS Capital Corporation
OFS Capital Corp is an externally managed, closed-end, non-diversified management investment company. Its business objective is to generate current income and capital appreciation by investing in middle-market companies in the United States. The company focuses on investments in senior secured loans, including first lien, second lien, and unitranche loans, as well as subordinated loans and, to a lesser extent, warrants, and other equity securities.